Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. director Jason P. Rhodes reported that investment entities associated with him sold a total of 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026.
The shares were sold at weighted-average prices around $21.14–$21.28, within disclosed ranges from $21.00 up to $21.61, under a Rule 10b5-1 trading plan adopted on March 19, 2026. The transactions were executed by Atlas Venture and related funds, and Rhodes disclaims Section 16 beneficial ownership of these securities except to the extent of his pecuniary interest. Following the sales, individual Atlas-affiliated entities continue to report sizeable indirect holdings, including 4,579,456 and 1,396,475 shares of Dyne Therapeutics common stock.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 2,362 shares of common stock at a weighted average price of $20.37 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting and settlement of restricted stock units.
After this transaction, Erick beneficially owns 121,563 shares of Dyne Therapeutics common stock, which includes 110,513 unvested restricted stock units that continue to tie a substantial portion of compensation to the company’s future performance.